ETFdb Logo
  • ETF Database
  • Content Hubs
    • Themes
      • Active ETF
      • Alternatives
      • Artificial Intelligence
      • China Insights
      • Core Strategies
      • Crypto
      • Disruptive Technology
      • Energy Infrastructure
      • ETF Building Blocks
      • ETF Investing
      • ETF Strategist
      • Financial Literacy
      • Fixed Income
      • Free Cash Flow
      • Future ETFs
      • Innovative ETFs
      • Institutional Income Strategies
      • Leveraged & Inverse
      • Market Insights
      • Market Outlooks
      • Modern Alpha
      • Nuclear Energy
      • Portfolio Strategies
      • Sector Investing
      • Tax Efficient Income
      • Thematic Investing
    • Asset Class
      • Equity
        • U.S. Equity
        • Int'l Developed
        • Emerging Market Equities
      • Alternatives
        • Gold/Silver/Critical Materials
        • Cryptocurrency
        • Currency
        • Volatility
      • Fixed Income
        • Investment Grade Corporates
        • US Treasuries & TIPS
        • High Yield Corporates
        • Int'l Fixed Income
    • ETF Ecosystem
    • ETFs in Canada
    • Market Outlook
    • Crypto ETF Hub
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Database Categories
    • Indexes
    • Scenario Analysis
    • Watchlists
    • Head-To-Head ETF Comparison Tool
    • Mutual Fund To ETF Converter
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
  • Research
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Sectors
    • Sector Investing Content Hub
    • XLK
    • XLI
    • XLU
    • XLY
    • XLP
    • XLRE
    • Sector Power Rankings
    • XLE
    • XLC
    • XLF
    • XLV
    • XLB
  • Multimedia
    • ETF 360 Video Series
    • ETF of the Week Podcast
    • Gaining Perspective Podcast
    • ETF Prime Podcast
    • Video
  • Company
    • About VettaFi
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Free sign up
    • Login
  1. Thematic Investing Content Hub
  2. As Lyft & Uber Struggled, IPO ETF Still Performed
Thematic Investing Content Hub
Share

As Lyft & Uber Struggled, IPO ETF Still Performed

Tom LydonJan 02, 2020
2020-01-02

Looking back at 2019, it’s fair to say some of the year’s most ballyhooed initial public offerings, such as Lyft (LYFT) and Uber (UBER), disappointed investors. It’s also fair to say the *Renaissance IPO ETF (IPO B-)* has been anything but disappointing as that ETF is higher by almost 34% as of Dec. 24.

IPO tracks the rules-based Renaissance IPO Index, which adds sizeable new companies on a fast entry basis and the rest upon scheduled quarterly reviews. Companies that have been public for two years are removed at the next quarterly review.

Additionally, the Renaissance IPO ETF is the only ETF focusing exclusively on the U.S. IPO Market. Renaissance Capital believes that IPO reinvents IPO investing by providing access to the U.S. IPO Market through an ETF, without investors having to buy IPOs individually.

“Renaissance Capital’s IPO Index, a basket of newly public companies, is up 33% this year versus a 29% rise in S&P 500,” reports CNBC. “More than half of newly listed companies were trading above their issue price at the end of the year, compared with about 40% last year, according to Renaissance Capital, which provides institutional research and IPO ETFs.”

Riding Along With This IPO

Ridesharing IPOs like Lyft and Uber may have sputtered off the starting line, but some IPOs like Slack are getting rave reviews from market analysts keeping an eye out on the latest offerings from Silicon Valley. Investors who haven’t warmed up to allocating capital into the IPO space can dip their toes in the water with exchange-traded funds (ETFs).

“Health-care and technology companies were the best performers for the fifth year in a row. Karuna Therapeutics took the top spot with a roughly 380% gain year to date,” reports CNBC. “Smith pointed to the FDA approving new immunotherapy and cancer drugs ‘faster than investors thought.’ Medical device companies also performed well and were widely seen as M&A targets, according to Smith.”

As of Oct. 31, IPO had a healthcare weight of 10.5%, according to Renaissance Capital data.

This article originally appeared on ETFTrends.com.


Content continues below advertisement

Loading Articles...

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X